Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 14 of 14 publications.

Oberprieler NG, Kovesdy CP, Layton JB, Thapa B, Curhan G, Farjat AE, Liu F, Johannes C, Vizcaya D. Clinical outcomes in US patients initiating finerenone – a report from the FOUNTAIN platform. Poster presented at the 61st European Renal Association (ERA) Congress; May 2024. Stockholm, Germany. [abstract] Nephrol Dial Transplant. 2024 May; 39(Suppl 1):i2271.

Williamson DB, Sohn CJ, Ito A, Haltiwanger RS. POGLUT2 and POGLUT3 O-glucosylate multiple EGF repeats in fibrillin-1, -2, and LTBP1 and promote secretion of fibrillin-1. J Biol Chem. 2021 Sep;297(3):101055. doi: 10.1016/j.jbc.2021.101055

Furze CM, Delso I, Casal E, Guy CS, Seddon C, Brown CM, Parker HL, Radhakrishnan A, Pacheco-Gomez R, Stansfeld PJ, Angulo J, Cameron AD, Fullam E. Structural basis of trehalose recognition by the mycobacterial LpqY-SugABC transporter. J Biol Chem. 2021 Jan;296:100307. doi: 10.1016/j.jbc.2021.100307

Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093

Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037

Price KJ, Knowles JA, Fox M, Wales JK, Heller S, Eiser C, Freeman JV, Brennan A, Basarir H, Stevens K, McPherson A. Effectiveness of the Kids in Control of Food (KICk–OFF) structured education course for 11–16 year olds with type 1 diabetes. Diabet Med. 2016 Feb;33(2):192-203. doi: 10.1111/dme.12881

Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663

Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliott J, Heller S. Assessing the cost‐effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2014 Apr;31(4):477-86. doi: 10.1111/dme.12371

Fleming A, Philip S, Prescott G, Olson J, Sharp P. Presence of retinopathy and a high microaneurysm count increase the risk of subsequent cardiovascular disease. Poster presented at the Diabetes UK professional conference 2014; March 5, 2014. Liverpool, UK. [abstract] Diabet Med. 2014 Mar 1; 31(S1):86-7. doi: 10.1111/dme.12378_2

Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, Heller S, Speight J. The cost-effectiveness of 5-week versus 1-week DAFNE structured education in type 1 diabetes: a preliminary evaluation using the Sheffield type 1 diabetes policy model. Diabet Med. 2013 Oct;30(10):1236-44. doi: 10.1111/dme.1227

Goatman KA, Philip S, Fleming AD, Harvey RD, Swa KK, Styles C, Black M, Sell G, Lee N, Sharp PF, Olson JA. External quality assurance for image grading in the Scottish diabetic retinopathy screening programme. Diabet Med. 2012 Jun 1;29(6):776-83. doi: 10.1111/j.1464-5491.2011.03504.x

Nielsen GL, Norgard B, Puho E, Rothman KJ, Sorensen HT, Czeizel AE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med. 2005 Jan 1;22(6):693-6.

Fenton M, Huang H, Hong Y, Hawe E, Kurz DJ, Erusalimsky JD. Early atherogenesis in senescence-accelerated mice. Exp Gerontol. 2004;39(1):115-22.

Kurz EU, Leader KB, Kroll DJ, Clark M, Gieseler F. Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon. J Biol Chem. 2000 May 5;275(18):13948-54.